Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other financing activities (2018 - 2024)

Capricor Therapeutics (CAPR) has 9 years of Other financing activities data on record, last reported at $2.3 million in Q4 2024.

  • For Q4 2024, Other financing activities rose 23.31% year-over-year to $2.3 million; the TTM value through Dec 2024 reached $9.8 million, up 32.1%, while the annual FY2024 figure was $9.8 million, 32.1% up from the prior year.
  • Other financing activities reached $2.3 million in Q4 2024 per CAPR's latest filing, up from $2.1 million in the prior quarter.
  • Across five years, Other financing activities topped out at $3.3 million in Q1 2024 and bottomed at $287807.0 in Q1 2020.
  • Average Other financing activities over 5 years is $1.3 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Other financing activities: soared 467.03% in 2020, then grew 1.13% in 2021.
  • A 5-year view of Other financing activities shows it stood at $473745.0 in 2020, then soared by 64.68% to $780150.0 in 2021, then soared by 47.18% to $1.1 million in 2022, then skyrocketed by 62.14% to $1.9 million in 2023, then rose by 23.31% to $2.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $2.3 million in Q4 2024, $2.1 million in Q3 2024, and $2.2 million in Q2 2024.